Ocuphire Pharma Inc reports results for the quarter ended in March - Earnings Summary

Opus Genetics

15/05/2023 14:32

* Ocuphire Pharma Inc  OCUP.OQ  reported a quarterly
adjusted loss
of 28 cents​​ per share for the quarter ended in March. The mean
expectation of five analysts for the quarter was for a loss
of 15 cents per share.
    * Revenue was $1.75 million​; analysts expected $2.95
million. 
    * Ocuphire Pharma Inc's reported EPS for the quarter was a
loss
of 28 cents​.
    * The mean earnings estimate of analysts had fallen by
about 10%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Ocuphire Pharma Inc shares had risen by 60.8% this
quarter and
gained 70.8% so far this year.
    * The company reported a quarterly loss of $5.79 million.
    * Wall Street's median 12-month price target for Ocuphire
Pharma
Inc is $22.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
15 at 01:32 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.15          -0.28          Missed
 Dec. 31 2022      0.97           1.58           Beat
 Sep. 30 2022      -0.29          -0.22          Beat
 Jun. 30 2022      -0.33          -0.25          Beat